natgillin/translations-raw huggingface dataset:
Sepsis* (ofte kaldet “blodforgiftning”, en alvorlig infektion med en betændelsesreaktion i hele kroppen, som kan føre til døden), øget antal hvide blodlegemer (eosinofili), for få blodplader (trombocytopeni), alvorlige allergiske reaktioner (anafylaktisk reaktion), overfølsomhedsreaktioner (såsom udslæt, kløe, vejrtrækningsbesvær, hvæsende åndedræt, hævelser i ansigtet og lavt blodtryk), lave blodsukkerniveauer (hos sukkersygepatienter), nervøsitet, søvnighed, nedsat syn, hurtig hjerterytme (puls), mundtørhed, maveuro, smagsforstyrrelser, unormal leverfunktion (japanske patienter har større sandsynlighed for at få denne bivirkning), hurtigt indsættende hævelse af hals og slimhinder (angioødem), som kan være dødelig, eksem, hudrødme, nældefeber, alvorligt medicinudløst udslæt, ledsmerter, smerter i arme og ben, senesmerter, influenzalignende symptomer, nedsat hæmoglobin samt forhøjet urinsyre, forhøjede leverenzymer eller forhøjet kreatinkinase i blodet. 
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia),low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, upset stomach, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect) , rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, , joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood.
• Medicin, som kan forhøje blodets indhold af kalium, såsom kaliumholdige saltsubstitutter, kaliumbesparende medicin (visse typer vanddrivende tabletter) ACE-hæmmere, angiotensin IIreceptorantagonister, non steroide antiinflammatoriske medicintyper (NSAID´er som acetylsalicylsyre og ibuprofen), heparin, lægemidler der undertrykker immunsystemet (som ciclosporin og tacrolimus) samt antibiotika indeholdende trimethoprim. 
• Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain 'water tablets'), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
Urinvejsinfektion, infektion i de øvre luftveje (som ondt i halsen, bihulebetændelse, almindelig forkølelse), blodmangel (anæmi), forhøjet kaliumindhold i blodet, besvær med at falde i søvn, tristhed (depression), besvimelse, svimmelhed, langsom puls (bradykardi), lavt blodtryk (hypotension) hos patienter i behandling for forhøjet blodtryk, svimmelhed når man rejser sig op (ortostatisk hypotension), stakåndethed, hoste, mavesmerter, diaré, maveubehag, oppustethed, opkastning, kløe, svedtendens, medicinudløst udslæt, rygsmerter, muskelkramper, muskelsmerter, nedsat nyrefunktion herunder akut nyresvigt, brystsmerter, træthedsfølelse og forhøjet kreatininniveau i blodet. 
Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood.
Udseende og pakningsstørrelser Pritor 40 mg tabletter er hvide aflange tabletter, hvorpå koden 51H er præget. 
What Pritor looks like and contents of the pack Pritor 40 mg tablets are white, oblong-shaped and engraved with the code '51H' on one.
Pritor 40 mg tabletter 
Pritor 40 mg tablets
Hvide aflange 3,8 mm tabletter, hvori koden 51H er præget. 
Pritor 40 mg tablets White oblong tablets of 3.8 mm engraved with the code number '51H' on one side.
Der er rapporteret reversible stigninger i serum-lithiumkoncentrationerne samt toksicitet ved samtidig behandling med lithium og ACE-hæmmere. 
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor antagonists, including telmisartan.
I prækliniske studier blev der ikke påvist nedsat fertilitet hos hunner eller hanner ved brug af telmisartan. 
In preclinical studies, no effects of Pritor on male and female fertility were observed.
Sepsis* (ofte kaldet "blodforgiftning", en alvorlig infektion med betændelsesreaktion i hele kroppen) eller hurtig hævelse af hud og slimhinder (angioødem). 
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately.
En tablet indeholder 20 mg telmisartan. 
Each tablet contains 20 mg telmisartan.
Lægemidler, der kan udløse hyperkaliæmi er kaliumholdige saltsubstitutter, kaliumbesparende diuretika, ACE-hæmmere, angiotensin II-receptorantagonister, non steroide antiinflammatoriske lægemidler (NSAIDs, herunder selektive COX-2-hæmmere), heparin, immunosuppressiva (cyclosporin eller tacrolimus) og trimethoprim. 
Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.
En tablet indeholder 80 mg telmisartan. 
Each tablet contains 80 mg telmisartan.
Metabolisme og ernæring Ikke almindelig: 
Anaphylactic reaction, hypersensitivity Metabolism and nutrition disorders Uncommon: Rare:
I den første periode af behandlingen skal blodtrykket kontrolleres regelmæssigt. 
At the beginning of the preventive therapy with Pritor 80 mg, blood pressure should be frequently monitored.
Udseende og pakningsstørrelser Pritor 80 mg tabletter er hvide aflange tabletter, hvorpå koden 52H er præget. 
What Pritor looks like and contents of the pack Pritor 80 mg tablets are white, oblong-shaped and engraved with the code '52H' on one.
Pritor 20 mg tabletter 
Pritor 20 mg tablets
Tabuleret liste over bivirkninger 
Tabulated list of adverse reactions
Bradykardi, svimmelhed, øget serumkreatinin og akut nyresvigt er også set. 
The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia, dizziness, increase in serum creatinine, and acute renal failure have also been reported.
Pritor 80 mg tabletter 
Pritor 80 mg tablets
Hvide aflange 4,6 mm tabletter, hvori koden 52H er præget. 
Pritor 80 mg tablets White oblong tablets of 4.6 mm engraved with the code number '52H' on one side.
Muligvis vil det være nødvendigt at stoppe brugen af anden medicin specielt, hvis det er noget af følgende: 
In some cases you may have to stop taking one of the medicines.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 40 mg telmisartan. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 40 mg telmisartan.
LÆGEMIDLETS NAVN Pritor 40 mg tabletter telmisartan 
NAME OF THE MEDICINAL PRODUCT Pritor 40 mg tablets telmisartan
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 20 mg telmisartan. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 20 mg telmisartan.
LÆGEMIDLETS NAVN Pritor 80 mg tabletter telmisartan 
NAME OF THE MEDICINAL PRODUCT Pritor 80 mg tablets telmisartan
Angioødem (også med letalt udfald), eksem, erytem, urticaria, medikamentelt udløst udslæt, toksisk hududslæt Knogler, led, muskler og bindevæv Ikke almindelig: 
Pruritus, hyperhidrosis, , rash Angioedema (also with fatal outcome), eczema, erythema, urticaria, drug eruption, toxic skin eruption
Telmisartan er en angiotensin II-receptorantagonist. 
Pritor belongs to a group of medicines known as angiotensin II receptor antagonists.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver tablet indeholder 80 mg telmisartan. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 80 mg telmisartan.
EU/1/98/089/011 (14 tabletter) EU/1/98/089/012 (28 tabletter) EU/1/98/089/020 (30 tabletter) EU/1/98/089/013 (56 tabletter) EU/1/98/089/019 (90 tabletter) EU/1/98/089/014 (98 tabletter) 
EU/1/98/089/011 (14 tablets) EU/1/98/089/012 (28 tablets) EU/1/98/089/020 (30 tablets) EU/1/98/089/013 (56 tablets) EU/1/98/089/019 (90 tablets) EU/1/98/089/014 (98 tablets)
LÆGEMIDLETS NAVN Pritor 20 mg tabletter telmisartan 
NAME OF THE MEDICINAL PRODUCT Pritor 20 mg tablets telmisartan
Nedenstående kombinationer frarådes. 
Concomitant use not recommended.
Dosis bør ikke overskride 40 mg hos patienter med let til moderat nedsat leverfunktion (se pkt. 
In patients with mild to moderate hepatic impairment the posology should not exceed 40 mg once daily (see section 4.4).
Alternativt, kan telmisartan anvendes i kombination med et diuretikum af thiazidgruppen, såsom hydrochlorthiazid. 
Alternatively, telmisartan may be used in combination with thiazide-type diuretics such as hydrochlorothiazide, which has been shown to have an additive blood pressure lowering effect with telmisartan.
Mht. det prædefinerede sekundære endepunkt (reduktion af kardiovaskulær død, ikke-letalt myokardieinfarkt og ikke-letal apopleksi) - som var identisk med det primære endepunkt i HOPEstudiet (The Heart Outcomes Prevention Evaluation Study) blev telmisartan fundet ligeværdig med ramipril [0,99 (97,5% CI 0,90-1,08, p (non-inferioritet) = 0,0004)]. 
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.901.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
• Obstruktive galdelidelser • Svært nedsat leverfunktion 
• Biliary obstructive disorders
Indehaver af markedsføringstilladelsen Bayer AG 
Marketing Authorisation Holder Bayer AG
Hud og subkutane væv Ikke almindelig: 
Hepatic function abnormal/liver disorder Skin and subcutaneous tissue disorders Uncommon: Rare:
EU/1/98/089/001 (14 tabletter) EU/1/98/089/002 (28 tabletter) EU/1/98/089/021 (30 tabletter) EU/1/98/089/003 (56 tabletter) EU/1/98/089/017 (90 tabletter) EU/1/98/089/004 (98 tabletter) EU/1/98/089/005 (280 tabletter) EU/1/98/089/015 (28 x 1 tablet) 
EU/1/98/089/001 (14 tablets) EU/1/98/089/002 (28 tablets) EU/1/98/089/021 (30 tablets) EU/1/98/089/003 (56 tablets) EU/1/98/089/017 (90 tablets) EU/1/98/089/004 (98 tablets) EU/1/98/089/005 (280 tablets) EU/1/98/089/015 (28 x 1 tablets)
EU/1/98/089/006 (14 tabletter) EU/1/98/089/007 (28 tabletter) EU/1/98/089/022 (30 tabletter) EU/1/98/089/008 (56 tabletter) EU/1/98/089/018 (90 tabletter) EU/1/98/089/009 (98 tabletter) EU/1/98/089/010 (280 tabletter) EU/1/98/089/016 (28 x 1 tablet) 
EU/1/98/089/006 (14 tablets) EU/1/98/089/007 (28 tablets) EU/1/98/089/022 (30 tablets) EU/1/98/089/008 (56 tablets) EU/1/98/089/018 (90 tablets) EU/1/98/089/009 (98 tablets) EU/1/98/089/010 (280 tablets) EU/1/98/089/016 (28 x 1 tablets)
Disse fund synes ikke at være af signifikant klinisk betydning og anses også for at være klasseeffekter ved ACE-hæmmere og andre angiotensin II-receptorantagonister,. 
These changes, also a class effect of angiotensin converting enzyme inhibitors and other angiotensin II receptor antagonists, do not appear to have clinical significance.
Hjælpestoffer, som behandleren skal være opmærksom på En tablet med 20 mg indeholder 84 mg sorbitol (E420). 
Each 20 mg tablet contains 84 mg sorbitol (E420).
Brystsmerter, asteni (træthed) 
Chest pain, asthenia (weakness) Influenza-like illness
Disse bivirkninger er sjældne (kan forekomme hos op til 1 ud af 1.000 brugere), men er meget alvorlige, og indtagelse af medicinen skal stoppe og læge straks kontaktes. 
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately.
LÆGEMIDLETS NAVN Pritor 20 mg tabletter Pritor 40 mg tabletter Pritor 80 mg tabletter 
NAME OF THE MEDICINAL PRODUCT Pritor 20 mg tablets
Mundtørhed, gastrointestinalt ubehag, dysgeusi 
Gastrointestinal disorders Uncommon:
Influenzalignende symptomer 
Hepatic impairment
Sepsis inklusive sepsis med letalt udfald 
Excipients with known effect
Insuman bør gives før måltiderne. 
Insuman should be given before meals.
Injektionsstedet ændres for hver injektion. 
The injection site is changed for each injection.
Se indlægssedlen for den præcise tidsplan. 
See the package leaflet for exact timings.
Dette er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Insuman. 
This is a summary of the European public assessment report (EPAR) for Insuman.
Den fuldstændige EPAR for Insuman findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
The full EPAR for Insuman can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Insuman den 21. februar 1997. 
The European Commission granted a marketing authorisation valid throughout the European Union for Insuman on 21 February 1997.
Pumpen må ikke implanteres i personer, der er fastboende i en højde på over 2 439 meter (8000 fod). 
The pump must not be implanted in people who reside permanently at elevations above at elevations above 2,439 metres (8000 feet).
Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Insuman. 
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Insuman.
Insuman kan forårsage hypoglykæmi. 
Insuman may cause hypoglycaemia.
Ved at holde blodsukkerniveauet under kontrol mindskes diabetessymptomerne og -komplikationerne. 
By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.
Patientens blodsukker bør kontrolleres regelmæssigt for at fastsætte den effektive minimumsdosis. 
The patient's blood glucose should be tested regularly to find the lowest effective dose.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Insuman. 
The Committee recommended that Insuman be given marketing authorisation.
Hvis du ønsker yderligere oplysninger om behandling med Insuman, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek. 
For more information about treatment with Insuman, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Det ønskede blodsukkerniveau og Insuman-produkt samt dosering og tidsplan for injektionerne fastlægges af lægen for hver patient individuelt og tilpasses dennes diæt, fysiske aktiviteter og livsstil. 
The desired blood glucose levels, the type of Insuman to be used, and the dose and timing of injections are determined by the doctor for each patient individually, and are adjusted to suit the patient's diet, physical activity and lifestyle.
Insuman Rapid kan også gives i en blodåre, men kun på en intensivafdeling eller tilsvarende facilitet, hvor patienten kan blive nøje overvåget. 
Insuman Rapid may also be given into a vein, but only in an intensive care unit or similar setting where the patient can be closely monitored.
Det må heller ikke anvendes hos patienter, som er overfølsomme over for titanlegeringer, polysulfon eller siliconemateriale anvendt i komponenter af den implanterede pumpe. 
It must also not be used in patients who are hypersensitive to titanium alloy, polysulfone or silicone material used in the components of the implanted pump.
Insuman må ikke anvendes hos personer, som er overfølsomme (allergiske) over for humant insulin eller andre af indholdsstofferne. 
Insuman must not be used in people who are hypersensitive (allergic) to human insulin or any of the other ingredients.
Erstatningsinsulinet fungerer på samme måde som naturligt produceret insulin og hjælper glukosen til at trænge ind i cellerne fra blodet. 
The replacement insulin acts in the same way as naturally produced insulin and helps glucose enter cells from the blood.
Det aktive stof i Insuman, human insulin, fremstilles ifølge en metode, der er kendt som "rekombinant dna-teknologi": Det fremstilles af bakterier, der har fået indsat et gen (DNA), som gør dem i stand til at producere insulin. 
The active substance in Insuman, human insulin, is produced by a method known as ‘recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced that makes the bacteria able to produce insulin.
Yderligere oplysninger om, hvordan Insuman gives, findes i produktresuméet (også en del af denne EPAR). 
Further information on the way Insuman is given can be found in the Summary of Product Characteristics (also part of the EPAR).
Insuman anvendes hos patienter med diabetes (type 1 og 2), som behøver behandling med insulin. 
Insuman is used in patients with diabetes (type 1 and 2) who need treatment with insulin.
Det primære effektmål i alle undersøgelserne var ændringen i koncentrationen af glykosyleret hæmoglobin (HbA1c), som er den procentdel af hæmoglobin i blodet, hvortil der er bundet glykose. 
The main measure of effectiveness in all studies was the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached.
Insuman Implantable må ikke anvendes på nogen anden måde og kan kun anvendes på centre, hvor personalet har fået tilstrækkelig undervisning i brug af den implantable pumpe. 
Insuman Implantable must not be used in any other way and can only be used in centres where staff have received adequate training in the use of the implantable pump.
Der må ikke anvendes nogen andre former for insulin med pumpen, og denne må ikke anvendes hos børn, der endnu ikke er på størrelse med en voksen. 
No other insulins must be used with the pump and the pump must not be used in children who have not yet reached adult size.
Den fuldstændige liste over alle de indberettede bivirkninger ved Insuman fremgår af indlægssedlen. 
For the full list of all side effects reported with Insuman, see the Package Leaflet.
Hvilken risiko er der forbundet med Insuman? 
What is the risk associated with Insuman?
Hvorfor blev Insuman godkendt? 
Why has Insuman been approved?
Insuman Rapid, Infusat, Basal og Comb gives ved injektion under huden, generelt i bugvæggen (maven) eller låret ifølge lægens anbefalinger. 
Insuman Rapid, Infusat, Basal and Comb are given by injection under the skin, generally in the abdominal wall (tummy) or the thigh, according to the doctor's recommendations.
Insuman indeholder forskellige former for insulin: den opløselige form, der er hurtigtvirkende (inden for 30 minutter efter injektionen), og isophan- og krystallinske protaminformer, der optages meget langsommere i løbet af dagen og dermed virker længere. 
Insuman contains insulin in various forms: the soluble form, which acts quickly (within 30 minutes of injection), and the isophane and crystalline-protamine forms, which are absorbed much more slowly during the day, giving them a longer duration of action.
Disse patienter fik Insuman Implantable som en kontinuerlig infusion i bughindehulen. 
These patients received Insuman Implantable as a continuous infusion into the peritoneal cavity.
Andre oplysninger om Insuman: 
Other information about Insuman
Insuman er en insulinerstatning, der svarer til det insulin, der produceres af kroppen. 
Insuman is a replacement insulin that is similar to the insulin made by the body.
Insuman Implantable anvendes hos patienter med type 1-diabetes, der ikke kan kontrolleres med insulin givet under huden, og som ofte oplever episoder af, i øvrigt uforklarlige, hyper- eller hypoglykæmi (for højt eller for lavt blodsukkerniveau). 
Insuman Implantable is used in adult patients with type 1 diabetes that cannot be controlled with insulin given under the skin and who often have episodes of, otherwise unexplained, hyper- or hypoglycaemia (high or low blood glucose levels).
• Insuman Comb, som fås i forskellige kombinationer af insuliner med hurtig eller mellemlang virkningstid. 
• Insuman Comb, which is available in various combinations of fast- and intermediate-acting insulins.
Insuman Rapid kan desuden anvendes til behandling af hyperglykæmisk koma (bevidstløshed forårsaget af for højt blodsukker) og ketoacidose (høje koncentrationer af ketoner [syrer] i blodet), samt til regulering af blodsukkeret før, under og efter en operation. 
Insuman Rapid can also be used for the treatment of hyperglycaemic coma (coma caused by too much blood glucose [sugar]) and ketoacidosis (high levels of ketones [acids] in the blood), and to control blood glucose before, during or after an operation.
Insuman har bevirket et fald i indholdet af HbA1c som tegn på, at blodsukkeret er blevet reguleret til et niveau svarende til det, der opnås med semisyntetisk humant insulin. 
Insuman led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with semi-synthetic human insulin.
Derudover blev Insuman Implantable undersøgt hos voksne patienter med type 1-diabetes. 
In addition, Insuman Implantable was studied in adult patients with type 1 diabetes.
• Insuman Rapid, Insuman Infusat og Insuman Implantable, der er hurtigtvirkende insulinopløsninger, der indeholder opløselig insulin 
• Insuman Rapid, Insuman Infusat and Insuman Implantable, which are fast-acting insulin solutions containing soluble insulin;
I en af undersøgelserne blev Insuman givet til patienter med type 1-diabetes ved hjælp af en ekstern insulinpumpe. 
In one of the studies, Insuman was given to patients with type 1 diabetes using an external insulin pump.
I en anden undersøgelse blev Insuman Comb 25 sammenlignet med semisyntetisk human insulin hos patienter med type 1- og type 2-diabetes. 
In another study, Insuman Comb 25 was compared with semi-synthetic human insulin in patients with type 1 and type 2 diabetes.
Insuman blev undersøgt i tre undersøgelser hos 780 patienter med enten type 1-diabetes eller type 2diabetes. 
Insuman has been studied in three trials in 780 patients with either type 1 diabetes or type 2 diabetes.
Endvidere må Insuman Implantable ikke anvendes på nogen anden måde end som kontinuerlig infusion ved hjælp af Medtronic MiniMed Implantable Pump. 
In addition, Insuman Implantable must not be used any other way than as a continuous infusion using the Medtronic MiniMed Implantable Pump.